Standard treatment and emerging drugs for managing synovial sarcoma: adult’s and pediatric oncologist perspective

Giacomo G. Baldi, Daniel Orbach, Rossella Bertulli, Chiara Magni, Giovanna Sironi, Michela Casanova, Andrea Ferrari

Research output: Contribution to journalReview articlepeer-review


Introduction: in this review we discuss the standard of care for both pediatric and adult synovial sarcoma (SS), the prognostic differences between them, and the treatments available for localized and advanced diseases. We also overview the biology and the recent drugs under consideration in clinical trials on SS. Areas covered: we focus on new targeted therapies being investigated for advanced SS, especially anti-angiogenic drugs, and immunotherapy. We review all the published data and ongoing trials dedicated to SS or to soft tissue sarcoma in general, paying particular attention to the results obtained in SS patients. Expert opinion: we expect new treatment strategies to become available for SS in the near future. The ongoing and published trials on targeted therapies and immunotherapy mainly concern adult patients, but the somatic biology of pediatric SS has some similarities as in adult disease. A stronger cooperation between adult and pediatric oncologists in recent years has led to a more shared effort to find new treatment strategies for advanced SS patients, regardless of their age.

Original languageEnglish
Pages (from-to)43-53
Number of pages11
JournalExpert Opinion on Emerging Drugs
Issue number1
Publication statusPublished - Jan 2 2019


  • Adoptive immunotherapy
  • adults
  • new drugs
  • NY-ESO 1
  • pediatric
  • standard treatment
  • synovial sarcoma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Standard treatment and emerging drugs for managing synovial sarcoma: adult’s and pediatric oncologist perspective'. Together they form a unique fingerprint.

Cite this